EP0767833A1 - Composition contenant de la collagenase et la chymopapaine pour isoler des hepatocytes et des cellules d'ilots pancreatiques - Google Patents

Composition contenant de la collagenase et la chymopapaine pour isoler des hepatocytes et des cellules d'ilots pancreatiques

Info

Publication number
EP0767833A1
EP0767833A1 EP96923189A EP96923189A EP0767833A1 EP 0767833 A1 EP0767833 A1 EP 0767833A1 EP 96923189 A EP96923189 A EP 96923189A EP 96923189 A EP96923189 A EP 96923189A EP 0767833 A1 EP0767833 A1 EP 0767833A1
Authority
EP
European Patent Office
Prior art keywords
nkat
collagenase
chymopapain
tissue
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96923189A
Other languages
German (de)
English (en)
Inventor
Catherine Lee
Cynthia Zerfass
Tan Thanh Dinh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Publication of EP0767833A1 publication Critical patent/EP0767833A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Definitions

  • the present invention generally relates to proteolytic enzyme compositions and procedures for digesting connec ⁇ tive tissue. More particularly, the present invention is directed to proteolytic enzyme compositions which can be used for reliably and reproducibly isolating hepatocytes and pancreatic islet cells and to the processes used for such cell isolation.
  • Proteolytic enzymes have found wide utility in a vari ⁇ ety of laboratory an clinical applications. Typically these applications involve cell dissociation and related therapeutic procedures which are benefitted by the ability of proteolytic enzymes to hydrolytically break-up or loosen connective tissue networks.
  • bacterial collagenase derived from Clostridium histolyticum has been used to disperse cells in laboratory tissue culture appli ⁇ cations.
  • collagenase has demonstrated util ⁇ ity in cell isolation procedures such as those associated with isolating pancreatic islets and dispersing a variety of tumor cells.
  • Other uses for collagenase involve its topical use in clinical applications in which collagenase compositions are applied in the treatment of burns or ulcers and wound healing.
  • chymopapain the major proteolytic component of the crude latex of Carica papaya, has been utilized in the treatment of abnormal or herniated discs to selectively dissolve the nucleus pulposus of the disc.
  • Other uses associated with chymopapain include its utility in cryosurgical healing processes.
  • Combinations of proteolytic enzymes such as composi ⁇ tions of bacterial collagenase and hyaluronidase are reportedly particularly useful for digesting or dissolving prostatic tissue in the treatment of benign prostatic hypertrophy.
  • the combination of these two proteolytic enzymes apparently dissolves prostatic tissue in order to relieve the obstructive symptoms of prostatic hypertrophy.
  • bacterial collagenase derived from Clostri- dium histolyticum has found utility in procedures involv ⁇ ing the dissociation and isolation of microvessel cells embedded in fatty tissues. These procedures generally in ⁇ volve combining fatty tissues having embedded microves- sels, such as liposuctioned fat, with collagenase under conditions which cause the collagenase to disrupt and di ⁇ gest the connective tissue. By carefully separating the cells from the digested tissue, viable microvessel cells are recovered.
  • microvessel cells have found particular utility as a coating on the interior of syn ⁇ thetic small diameter vascular grafts implanted in humans and animals to replace blood vessels.
  • micro- vessel cells are useful as deposits on the surface of bio- medical implant devices in general where they provide an improved biocompatibility to the implant.
  • the microvessel cells contribute to the prevention of protein deposits and related cellular deposits on the implants which are known to occur when foreign materials are placed in contact with blood and tissue. In the case of vascular grafts these deposits can quickly cause the vessel to occlude, resulting in the functional failure of the graft.
  • connective tissues are formed largely of collagen, for which collagenase is specific in its hydro- lytic activity, significant amounts of other proteins and glycoproteins are additionally found in connective tissue matrices. Thus, collagenase alone may not effectively hydrolyze all of the tissue mixtures.
  • collagenase derived from native bacteria dif ⁇ fers widely in its collagen specific hydrolytic activity and the amount and character of impurities, including other proteases and toxins.
  • the protease impurities in crude collagenase contribute to the hydrolysis of minor proteins in connective tissue and actually aid in the di ⁇ gestive process.
  • protease impuri ⁇ ties are active with proteins generally and can damage cells.
  • Proteases can also react with collagenase, causing the crude collagenase to be subject to catalytic degrada ⁇ tion.
  • the toxin impurities associated with crude colla ⁇ genase can be a serious problem for procedures involving both in vivo and in vitro applications. Toxins can dis ⁇ rupt cell membranes, destroy cell viability and generally lower cell yield. Additionally, impurities can contain variable amounts of bacterial DNA, which may cause cell -4 - PATENT
  • Another object of the present invention is to provide proteolytic enzyme compositions capable of digesting con ⁇ nective tissue in a reproducible and predictable manner.
  • the present invention accomplishes the above objec ⁇ tives by providing proteolytic enzyme compositions capable of predictably and reproducibly digesting tissue contain- ing hepatocytes and pancreatic islet cells. Further, the present invention provides processes for digesting tissue and dissociating cells from the connective tissue, provid ⁇ ing efficaciously viable hepatocytes and pancreatic islet cells in high yield. The viable cells thereby provided have utility in a variety of in vivo and in vitro applications.
  • the present invention is based upon the discovery that, although neither collagenase nor chymopapain alone is effective to digest tissue, a mixture of collagenase and chymopapain can be used to safely, reproducibly and reliably digest connective tissue formed of a variety of proteins and glycoprotein extracellular matrix material.
  • compositions of purified collagenase and chymopapain have been found to effectively digest connective tissue and reproducibly dissociate and isolate cells embedded in the tissue, -6 -
  • the isolated cells in high yield. Moreover, because the isolated cells have been processed with compositions of purified enzymes, the cell suspensions are essentially free of the harmful effects of toxins and unknown unreactive materials, making them highly viable and safe for in vivo use.
  • the present invention provides novel enzyme compositions and associated methodologies useful for hydrolyzing connective tissue in biological systems.
  • the enzyme compositions of the present invention principally comprise a combination of collagenase, in an amount sufficient to hydrolyze collagen in the biological system, and chymopapain in an amount sufficient to hydrolyze chymopapain active tissue in the biological system.
  • the collagenase and chymopapain are purified and essentially free of toxic components, such as bacterial DNA and sensitizing antigens, and the collagenase is essentially free of non-collagen specific components. It is also within the scope of the present invention to provide associated processes utilizing these enzyme compositions of collagenase and chymoparain.
  • An exemplary process of the present invention includes enzymatically digesting connective tissue by providing an enzyme compo ⁇ sition of collagenase, essentially free of collagen inac ⁇ tive components and toxins and in an amount sufficient to hydrolyze the collagen present in the connective tissue, and chymopapain essentially free of toxins and in an amount sufficient to hydrolyze chymopapain active tissue in the connective tissue.
  • an enzyme compo ⁇ sition of collagenase essentially free of collagen inac ⁇ tive components and toxins and in an amount sufficient to hydrolyze the collagen present in the connective tissue
  • chymopapain essentially free of toxins and in an amount sufficient to hydrolyze chymopapain active tissue in the connective tissue.
  • a preferred process of the present invention utilizes the above steps to hydrolyze connective tissue in order to dissociate and isolate hepatocytes and pancreatic islet cells embedded in the tissue.
  • hepatocytes and pancreatic islet cells which form part of the mixture are dissociated from the connective tissue and isolated in higher yield and have improved via ⁇ bility when compared with cells isolated from tissue hy- drolyzed according to prior art procedures which utilize crude collagenase.
  • the higher yield of such cells pro ⁇ vided by the processes of the present invention is charac- terized by the increased number of viable healthy cells.
  • the increased yield as well as increased viability and integrity of cells isolated according to the processes of the present invention are readily demonstrated by labora ⁇ tory testing techniques.
  • cell-counting techniques provide cell size information and information relating to the distribution of cell sizes in a given batch of isolated cells.
  • cell function and ef ⁇ ficacy are demonstrated by their biological function, such as production of insulin by pancreatic islet cells in re- sponse to glucose concentration change in culture media. This response is characterized by the ratio of insulin production in the presence of glucose to the base-line value.
  • Fig. 1 illustrates the particle size distribution of rat hepatocyte cells isolated using crude collagenase in accordance with the prior art
  • Fig. 2 illustrates the particle size distribution of rat hepatocyte cells isolated using purified collagenase- chymopapain enzyme compositions in accordance with the present invention
  • Fig. 3 illustrates the static incubation glucose response by porcine pancreatic islet cells isolated using crude collagenase according to the prior art
  • Fig. 4 illustrates the static incubation glucose response by porcine pancreatic islet cells isolated using purified collagenase-chymopapain enzyme compositions according to the present invention.
  • the present invention provides proteolytic enzyme compositions and processes capable of predictably and reproducibly digesting physiological connective tissue in a variety of therapeutic and laboratory applications. These applications range from in vivo therapeutic treat ⁇ ment procedures to techniques which involve dissociating and isolating cells embedded in connective tissue for subsequent laboratory or clinical applications.
  • the compositions and processes of the present inven ⁇ tion are suitable for reproducibly hydrolyzing or digest ⁇ ing a wide variety of collagens, non-collagenous connective tissue proteins, glycoproteins, and extracellular matrix materials.
  • Those skilled in the art will appreciate that the ability to hydrolyze a wide range of proteins and protein mixtures makes the teachings of the present invention widely applicable in a number of in vivo as well as in vitro tissue digestion procedures.
  • compositions and processes of the present inven- tion find particular application in cell dissociation pro ⁇ cedures including laboratory cell culture methods and re- lated cell isolation techniques.
  • cells can be effectively and reproduc ⁇ ibly isolated from a host of different proteinaceous con ⁇ nective tissues and harvested in higher yield with im- proved preservation of the cell membranes.
  • these cells have better viability and are free of toxins and contaminants, when compared with cells isolated using prior art processes.
  • compositions and processes of the present invention are particularly suitable for isolating hepatocytes and pancreatic islet cells embedded in connective tissues for subsequent util ⁇ ity in various clinical procedures such as transplanting hepatocytes or pancreatic islet cells into individuals suffering from liver, pancreatic, or other types of diseases.
  • the enzyme compositions of the present invention include purified collagenase in an amount sufficient to hydrolyze collagen present in the system, and chymopapain in an amount sufficient to hydro- lyze chymopapain active tissue in the system.
  • the colla ⁇ genase and the chymopapain are purified and essentially free of toxic components such as bacterial components and sensitizing antigens.
  • the collagenase is free of collagen inactive components.
  • Preferred exemplary embodiments of the present inven ⁇ tion are solutions of collagenase and chymopapain in a physiologically compatible liquid.
  • Suitable physiologi ⁇ cally compatible liquids include phosphate buffered saline solutions and similar buffered electrolyte solutions hav- ing osmolalities which are compatible with physiological tissue.
  • a particularly suitable commercially available electrolyte solution is Plasmalyte® electrolyte solution available from Baxter-Hyland, having a buffered pH of 7.4 and an osmolarity of 294 mOsmol/L obtained with controlled concentrations of sodium, potassium, magnesium, chloride, acetate, and gluconate ions.
  • addi- tives such as human serum albumin and serum are preferred in many applications.
  • compositions of the present invention include a solution of from about 25 nkat/ml to about 120 nkat/ml purified collagenase and from about 0.15 nkat/ml to about 0.55 nkat/ml purified chymopapain in a suitable pH buf ⁇ fered physiologically compatible liquid.
  • the nkat/ml unit is defined as nanomoles of substrate hydrolyzed per second by 1 ml of enzyme solution under the assay condition used.
  • enzyme activity assays were conducted at 37°C.
  • the enzyme composition is a solution of 30 nkat/ml purified collagenase and 0.3 nkat/ml chymopapain in a solution of about 0.4 wt% human serum albumin in Plasmalyte® electrolyte solution for the isolation of hepatocytes and a solution of from about 25 nkat/ml to about 120 nkat/ml of purified collagenase and about 0.15 nkat/ml to about 0.55 nkat/ml chymopapain for pancreatic islet cells.
  • collagenase is derived from the bac ⁇ terium Clostridium histolyticum and in its crude form dif ⁇ fers from batch to batch in hydrolytic activity and pur ⁇ ity. Uncontrolled amounts of impurities found in crude collagenase may include contaminating bacterial compo ⁇ nents, pigment, pyrogens, proteases, and peptidases, including clostripain, trypsin, and caseinase.
  • purified collagenase suitable for use in the compositions of the present invention, is substantially free of pigment, bacterial components, and nonspecific enzyme activity. Crude collagenase is readily available from a number of commercial sources including Sigma Chemical Company of St.
  • purified collagenase suitable for use in accordance with the present invention exhibits a batch-to-batch uniformity in specificity for collagen as well as toxin-free characteristics.
  • chymopapain a proteolytic enzyme extracted from papaya latex
  • Chymopapain is commercially available in a dry lyophilized state from a number of sources including Sigma Chemical of St. Louis, Missouri.
  • Chymopapain is available in crude, partially purified, and more highly purified forms which differ in the amount of papain, lysozyme pep- tidase A and sensitizing antigens found in the prepara- tion.
  • Chymopapain suitable for use in the present inven ⁇ tion is characterized as having essentially no immunogen ⁇ icity and essentially no toxicity as a result of purifica ⁇ tion processes.
  • Chymopapain from most commercial sources which has been purified using known chromatographic purif- ication processes, provides chymopapain suitable in the practice of the present invention.
  • puri- fied chymopapain can be prepared using, for example, the process described in U.S. Patent No. 4,719,108.
  • connective tissue which holds cells together, is a com ⁇ plex mixture of collagen, other extracellular proteins, glycoproteins, and mucopolysaccharides. Purified colla ⁇ genase alone will not effectively hydrolyze all of this extracellular matrix material. However, it has been dis- covered by the present inventors that by combining puri ⁇ fied collagenase with toxin-free chymopapain a wide range of connective tissue systems and biologically derived raw materials can be predictably digested.
  • the hy ⁇ drolyzed tissues and cells isolated during these hydroly- sis processes are free of antigenic components which can cause anaphylactic shock if present in cells or tissues implanted or digested in vivo. Accordingly, cells iso ⁇ lated in accordance with the present invention for subse ⁇ quent implantation do not present toxic health hazards to their recipients. Similarly, the compositions of the present invention can be utilized for in vivo procedures with little risk of anaphylactic shock.
  • the enzyme compositions of the present invention can be prepared according to processes known in the art. Typically, these processes involve mixing the two enzymes in a selected physiologically compatible liquid such as phosphate buffered normal saline solution or Plasmalyte® electrolyte solution containing human serum albumin (HSA) and CaCl 2 . Then lyophilizing the resulting aqueous solu- tion provides a stable dry enzyme preparation which can be reconstituted with deionized water. Preferably, the com ⁇ positions are reconstituted just prior to their use in order to minimize any degradation that may occur once the enzymes are placed in solution.
  • a selected physiologically compatible liquid such as phosphate buffered normal saline solution or Plasmalyte® electrolyte solution containing human serum albumin (HSA) and CaCl 2 .
  • HSA human serum albumin
  • CaCl 2 CaCl 2
  • the prepared enzyme compositions are main ⁇ tained at reduced temperatures in the range of about 4°C ⁇ 2°C until their use.
  • separate stock solutions of each enzyme which typically include concen ⁇ trated forms of the enzyme in a buffered saline solution, can be prepared in advance and stored frozen at about -80°C. Just prior to use, the solutions are thawed, diluted with a suitable physiologically compatible diluent to a desired enzyme activity or concentration, and then combined, to form the enzyme composition.
  • Suitable diluents include aqueous based solutions buffered to a pH of about 7.4 and having a physiologically compatible osmolarity.
  • the processes of the present invention broadly include providing a composition of the present invention and causing the composition to contact selected tissue for a length of time and at a temperature sufficient to substantially hydrolyze the tissue and permit isolation of hepatocytes and pancreatic islet cells.
  • Preferred exemplary processes in accordance with the teachings of the present invention include digesting connective tissue for the purpose of dissociating and isolating cells embedded in the connective tissue.
  • the compositions of. the present invention provide highly viable cells which are particularly useful for gene therapy and transplanting into humans or animals for therapeutic purposes.
  • pancreatic cells can be isolated from donor pancreases and transplanted into humans or animals for purposes of treating pancreatic related diseases.
  • hepatocytes can be isolated from liver in accordance with known procedures utilizing compositions of the present invention.
  • a most preferred process of the present invention in ⁇ cludes providing an appropriate enzyme composition of the present invention and contacting the enzyme composition with connective tissue for a length of time and at a tem ⁇ perature sufficient to substantially hydrolyze the connec ⁇ tive tissue and to isolate hepatocytes and pancreatic islet cells embedded in the tissue.
  • an exemplary preferred pro ⁇ cess for digesting tissue includes the steps of providing an enzyme composition of a Plasmalyte® electrolyte solu ⁇ tion of about 25 nkat/ml to about 120 nkat/ml purified collagenase, about 0.15 nkat/ml to about 0.55 nkat/ml chy- mopapain and about 0.4 wt% human serum albumin.
  • the enzyme composition at about 37°C is perfused into the organ containing the tissue to be digested, for example, a liver or pancreas, by means of cannulation in an amount of about 1-10 ml of enzyme composition per gram of organ weight until the organ is sufficiently expanded to permit dissection, incubation of the combination of cells and partially hydrolyzed tissue, and isolation of the desired viable hepatocytes or islet cells.
  • Further separation of viable cells from the incubated combination can be accomplished by shaking the incubated combination until hydrolyzed tissue separates from a supernatant containing cells. The cells are then separ ⁇ ated from the supernatants by centrifugation and pipeting off the supernatants.
  • Preferred exemplary processes fur- ther include rinsing the cells with a physiologically compatible liquid prior to their evaluation and use.
  • Tissues which are subject to digestion in accordance with the present invention should have good contact with the enzyme solution. Accordingly, large pieces of tissue should be minced with a pair of scissors prior to further treatment. Additionally, the tissue is preferably rinsed with a physiologically compatible rinsing solution in order to remove visible blood contaminants including clotted blood. Suitable rinsing solutions include those having pH ranges and osmolarity ranges which are compat ⁇ ible with cellular material, such as phosphate buffered saline and Plasmalyte® electrolyte solution.
  • a preferred method for rinsing the mixture involves .transferring the tissue into a sieve-tissue grinder cup and adding phos ⁇ phate buffered saline solution to the mixture while stir ⁇ ring. Excess liquids and blood contaminants are removed by the rinsing and sieving process. The homogenized and rinsed mixture is then prepared for the above-described digestion and cell isolation procedures.
  • hepatocytes and pancre ⁇ atic islet cells isolated from hydrolyzed tissues in accordance with the teachings of the present invention are isolated in higher yields and have greater viability than cells isolated by prior art processes.
  • the enzyme compositions used in the processes of the pres ⁇ ent invention are free of toxins, in the event that iso- lated cells are implanted for therapeutic purposes or are subjected to other in vivo uses, any residual cotrans- planted enzyme composition will not pose the threat of an anaphylactic or other adverse response.
  • the superior physical and functional characteristics of the cells isolated according to the process of the present invention are sometimes demonstrated by the higher yield of cells having expected characteristics as deter ⁇ mined by known cell-counting methods.
  • Other indicators of the superior results obtained by the present invention in- elude the higher insulin production response to glucose concentration in culture media by pancreatic islet cells isolated in accordance with this invention.
  • a higher yield of these cells, as produced by the present invention is an indicator of a highly safe and efficacious process.
  • digesting porcine pancreatic tissue utilizing purified collagenase without chymopapain being present resulted in no porcine islet cells being isolated.
  • a comparable procedure utilizing an enzyme composition of purified collagenase at 100 nkat/ml and chymopapain at 0.3 nkat/ml in an electrolyte solution provided an average of 228,800 islet cells.
  • the resultant superior physical and functional charac ⁇ teristics of cells isolated according to the present in ⁇ vention make them particularly useful for transplanting.
  • the high viability and functional ability of these cells provide a transplant that is less susceptible to func ⁇ tional failure.
  • Sprague Dawley of Fisher 344 male rats 8-16 weeks old, 125-350 G, were brought to an animal facility one week before being used as liver donors and were maintained on a 12-hour dark/light cycle.
  • each rat was anesthetized following a standard animal operating procedure. Heparin, 500 u, was administered by intraperi- toneal injection. The abdominal area was cleaned with betadine and opened through a idline incision. A 16- gauge catheter was inserted into the inferior vena cava and secured with a silk tie. While getting the animal ready, calcium-free HEPES-saline buffer and enzyme solu- tion were warmed in a 37°C water bath.
  • a tubing linked to a pump for perfusion was inserted into buffer or enzyme solution.
  • the other end of the perfusate tubing was con ⁇ nected to a cannula.
  • the flow of calcium-free HEPES- saline buffer, pH 7.4 was initiated at 25 ml/minute for 5- 6 minutes.
  • An incision was made on the diaphragm and the inferior vena cava was clamped in the thorax.
  • the portal vein was cut to allow efflux of the buffer.
  • the perfusion was switched, via stopcock, to the collagenase-chymopapain solution and continued for 5-10 minutes.
  • the liver the average weight of which was about 20 g, was significantly distended and the internal structure began to loosen up and showed signs of collapsing.
  • the liver was carefully dissected free and placed on ice in a ster ⁇ ile petri dish containing William's E. media.
  • the liver capsule was peeled back and the hepatocytes were dispersed by gentle shaking.
  • the liver cell suspension was filtered through a 300 ⁇ m mesh filter into a 50 ml sterile centri ⁇ fuge tube and allowed to settle by gravity for 15 minutes, followed by brief centrifugation.
  • the cells were washed three times with sterile HEPES-saline, and the volume was reduced by 50% after each wash.
  • a small aliquot of cell suspension was mixed into isotonic solution.
  • the cell concentration and size distribution were analyzed with a Coulter Counter fitted with a multisizer unit.
  • a total of 8xi0 7 hepatocytes of 90% viability were isolated using crude collagenase compared to a total of 12xl0 7 hepatocytes at 95% viability using the purified collagenase and chymopapain mixture.
  • Figs. 1 ad 2 illustrate the particle size distribution of hepatocytes isolated using the enzyme composition of the present invention (Fig. 2) compared to using crude collagenase (Fig. 1) .
  • the .viable cells recovered using the collagenase- chymopapain mixture were less damaged and were isolated in a higher yield than those using crude collagenase, as can be seen by comparing the 20-30 ⁇ range of the curve shown in Fig. l, which represents the particle size distribution of hepatocytes isolated using crude collagenase with that of the curve shown in Fig. 2, which represents the parti ⁇ cle size distribution of hepatocytes isolated using the purified collagenase-chymopapain enzyme composition of this invention.
  • the following example illustrates the isolation of porcine pancreatic islet cells.
  • Example 2 Enzyme solutions were prepared according to the proce ⁇ dure of Example 1 except that Hanks balanced salt solution (HBSS) containing CaCl 2 was used instead of HEPES-saline buffer solution.
  • HBSS Hanks balanced salt solution
  • the pancreas was weighed and the duct cannulated.
  • Warm enzyme solution in a volume of 4 ml/g of tissue was used to expand the organ by injecting through the duct using a 30 ml syringe. Run-off solution was collected into a tray.
  • the pancreas was then cut into large pieces approximately one inch in diameter and loaded into a container together with all the enzyme solution used for organ expansion.
  • the container with tissue was carefully sealed and agitated by gentle mechanical shaking in a 37°C water bath for 12 minutes or until the majority of the tissue was digested into small fragments.
  • the digested tissue was filtered through a 3 mm screen into another container, placed on -ice, and digested further by gentle manual stirring.
  • the following example illustrates the effect upon cell function of isolating porcine pancreatic islet cells using the enzyme composition of the present invention compared to using crude collagenase.
  • Example 3 Using the porcine pancreatic cells isolated according to the procedure of Example 2, static incubation glucose responses were plotted over time for cells isolated using crude collagenase, shown in Fig. 3, and for cells isolated using the purified collagenase-chymopapain enzyme composi ⁇ tion of the present invention, shown in Fig. 4.
  • Insulin which is a measure of cell function can be seen to have a higher value in the case of the curve plotted in Fig. 4 than in Fig. 3. This is an indication that the islet cells isolated using the enzyme composition of the present invention function more normally than islet cells isolated using the crude collagenase of the prior art.
  • the following example illustrates the isolation of rat islet cells.
  • Example 2 The procedure of Example 2 was followed except that, due to the small quantities of purified enzyme used, the pancreas was expanded with HBSS solution, then cut into pieces approximately 0.5 cm in diameter. About 2.5 g of tissue was suspended in 10 ml enzyme solution in a vial with screw cap. The vial was carefully sealed and agi ⁇ tated in a 37°C water bath until most of the tissue pieces appeared to be disintegrated. Digestion was also moni ⁇ tored by sampling of tissue suspension periodically and staining the islets with dithizone solution. Incubation and shaking were stopped when the majority of the islets was released but before damage to the islets was detected. The results are shown in Table II.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne des compositions d'enzyme protéolytique et des procédés permettant d'isoler des hépatocytes et des cellules d'îlots pancréatiques dans des tissus les contenant. Ces compositions enzymatiques renferment de la collagénase, laquelle est pratiquement dépourvue de toxines et de constituants spécifiques non collagéniques, et de la chymopapaïne, laquelle est pratiquement dépourvue de toxines. Ces compositions enzymatiques contiennent de préférence un mélange aqueux de collagénase présentant une activité de 25 nkat/ml à environ 120 nkat/ml, et de la chymopapaïne présentant une activité d'environ 0,15 nkat/ml à environ 0,55 nkat/ml.
EP96923189A 1995-04-25 1996-04-24 Composition contenant de la collagenase et la chymopapaine pour isoler des hepatocytes et des cellules d'ilots pancreatiques Withdrawn EP0767833A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42874995A 1995-04-25 1995-04-25
US428749 1995-04-25
PCT/US1996/005725 WO1996034093A1 (fr) 1995-04-25 1996-04-24 Composition contenant de la collagenase et la chymopapaine pour isoler des hepatocytes et des cellules d'ilots pancreatiques

Publications (1)

Publication Number Publication Date
EP0767833A1 true EP0767833A1 (fr) 1997-04-16

Family

ID=23700250

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96923189A Withdrawn EP0767833A1 (fr) 1995-04-25 1996-04-24 Composition contenant de la collagenase et la chymopapaine pour isoler des hepatocytes et des cellules d'ilots pancreatiques

Country Status (4)

Country Link
EP (1) EP0767833A1 (fr)
JP (1) JPH10508205A (fr)
CA (1) CA2193354A1 (fr)
WO (1) WO1996034093A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530066A (ja) * 1999-04-06 2003-10-14 ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア ヒトニューロゲニン３をコードするヌクレオチド配列
US6967019B2 (en) 1999-04-06 2005-11-22 The Regents Of The University Of California Production of pancreatic islet cells and delivery of insulin
US8193330B2 (en) 1999-04-06 2012-06-05 The Regents Of The University Of California Polynucleotides comprising Neurogenin3 promoter and bHLH encoding domains
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7169405B2 (en) 2003-08-06 2007-01-30 Warsaw Orthopedic, Inc. Methods and devices for the treatment of intervertebral discs
US7504201B2 (en) * 2004-04-05 2009-03-17 Organ Recovery Systems Method for perfusing an organ and for isolating cells from the organ
WO2007031098A1 (fr) 2005-09-12 2007-03-22 Xigen S.A. Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk
US8642060B2 (en) 2006-04-24 2014-02-04 Warsaw Orthopedic, Inc. Controlled release systems and methods for osteal growth
US7879027B2 (en) 2006-04-24 2011-02-01 Warsaw Orthopedic, Inc. Controlled release devices for fusion of osteal structures
US7771414B2 (en) 2006-04-24 2010-08-10 Warsaw Orthopedic, Inc. Controlled release devices for therapeutic treatments of spinal discs
US8642059B2 (en) 2006-04-24 2014-02-04 Warsaw Orthopedic, Inc. Controlled release systems and methods for intervertebral discs
WO2009143864A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de maladies digestives inflammatoires chroniques ou non chroniques
WO2009143865A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
WO2010072228A1 (fr) 2008-12-22 2010-07-01 Xigen S.A. Nouvelles constructions transporteuses et molécules conjuguées cargo/transporteuses
WO2011160653A1 (fr) 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
WO2013091670A1 (fr) 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies
WO2014206427A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies
CN105307670A (zh) 2013-06-26 2016-02-03 埃克西金炎症有限公司 Jnk信号转导途径的细胞渗透肽抑制剂用于治疗多种疾病的新用途
WO2015197097A1 (fr) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CZ309541B6 (cs) * 2021-08-30 2023-03-29 MB PHARMA s.r.o. Kmen produkující clostripain-like protein pro použití ve směsi s rekombinantní kolagenázou ColG a ColH pro izolaci Langerhansových ostrůvků pankreatu

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000580A1 (fr) * 1992-06-22 1994-01-06 Trigen, Inc. CLONAGE MOLECULAIRE DES GENES RESPONSABLES DE LA PRODUCTION DE COLLAGENASE A PARTIR DE $i(CLOSTRIDIUM HISTOLYTICUM)
US5422261A (en) * 1993-04-16 1995-06-06 Baxter International Inc. Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9634093A1 *

Also Published As

Publication number Publication date
CA2193354A1 (fr) 1996-10-31
JPH10508205A (ja) 1998-08-18
WO1996034093A1 (fr) 1996-10-31

Similar Documents

Publication Publication Date Title
US5422261A (en) Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
WO1996034093A1 (fr) Composition contenant de la collagenase et la chymopapaine pour isoler des hepatocytes et des cellules d'ilots pancreatiques
US5753485A (en) Purified mixture of collagenase I, collagenase II and two other proteases
EP0907723B1 (fr) Composition enzymatique pour la dissociation tissulaire
US5079160A (en) Method to isolate clusters of cell subtypes from organs
EP0695350B1 (fr) Procede de purificatin de collagenase
Williams et al. Collagenase lot selection and purification for adipose tissue digestion
US5989888A (en) Purified mixture of collagenase I, collagenase II and two other proteases
US6146626A (en) Defined enzyme mixtures for obtaining cells and treating wounds
Wilson et al. [18] Preparation and maintenance of adrenal medullary chromaffin cell cultures
EP0857202B1 (fr) Procede d'inhibition de l'activite enzymatique de la chymopapaine et de la papaine au moyen de polysaccharides d'origine animale
WO1994024273A1 (fr) Compositions stables a base de collagenase et procedes de preparation
Samejima et al. Gelatin density gradient for isolation of islets of Langerhans
Nečas et al. Effect of proteases, phospholipases and polysaccharide-splitting enzymes on plasma membrane particles and on the synthesis of the fibrillar cell wall component in yeast protoplasts
WO1997014788A1 (fr) Procede d'inhibition de l'activite de la chymopapaïne et de la papaïne avec des ions zinc
KR19980703053A (ko) 세포 수득 및 상처 치료를 위한 새로운 확정 효소 혼합물
WO1994004666A1 (fr) Procedes de purification de la collagenase
MXPA96006138A (en) A purified mixture of colagenases and other two proteins obtained from clostridium histolyti

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DINH, TAN THANH

Inventor name: ZERFASS, CYNTHIA

Inventor name: LEE, CATHERINE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19980317